

# Ventricular Assist Device Market Worth \$3.3 Bn by 2032, Driven by Advancements in Technology & Heart Failure Prevalence

*Fueled by increasing heart failure cases, technological innovations, and rising investment in VAD research, projected to grow at a CAGR of 8.8% from 2024-2032.*

AUSTIN, TX, UNITED STATES, January 30, 2025 /EINPresswire.com/ -- According to Research by SNS Insider, The [Ventricular Assist Device market](#) size valued at USD 1.6 billion in 2023, is poised for substantial growth, projected to reach USD 3.3 billion by 2032, reflecting a robust CAGR of 8.8% from 2024 to 2032.



## Technological Advancements and Rising Heart Failure Cases Propel Growth in the Ventricular Assist Device Market

The ventricular assist devices (VAD) market is rapidly expanding due to the increasing occurrence of heart failure and progress in medical technology. Worldwide, more than 26 million individuals are affected by heart failure, with over half experiencing death within five years of being diagnosed. By the year 2030, more than 8 million adults in the United States are expected to suffer from heart failure. Technological advancements, including smaller devices, better biocompatibility, and increased durability, are driving market growth. Recent VAD models show improved patient outcomes and expand their application beyond heart transplant assistance, offering prolonged treatment for those not eligible for surgery. Enhanced educational initiatives and venture capital funding are driving the research and development of next-generation VADs even further. Collectively, these elements position VADs as a key area in tackling the worldwide challenge of heart failure.

Get a Free Sample Report of Ventricular Assist Device Market @ <https://www.snsinsider.com/sample-request/4568>

Key Players in Ventricular Assist Device Market

- Abbott Laboratories – (HeartMate 3 LVAD, HeartMate II LVAD)
- Medtronic – (HVAD System, Medtronic Cardiac Resynchronization Therapy (CRT))
- Jarvik Heart Inc. – (Jarvik 2000 LVAD, Jarvik 15mm Pediatric VAD)
- Berlin Heart GmbH – (EXCOR Adult, EXCOR Pediatric)
- Abiomed – (Impella 2.5, Impella CP)
- Terumo Corporation – (DuraHeart LVAD, CAPIOX heart-lung machines)
- Getinge AB – (Cardiohelp System, Rotaflow Centrifugal Pump)
- LivaNova PLC – (HeartWare HVAD, Perceval Sutureless Heart Valve)
- ReliantHeart Inc. – (HeartAssist 5 LVAD, aVAD LVAD)
- Sun Medical Technology Research Corp. – (Toyobo LVAD, SM-LVAD System)
- CorWave – (CorWave LVAD, CorWave membrane pump technology)
- Evaheart, Inc. – (EVAHEART LVAD, EVAHEART 2 LVAD)
- SynCardia Systems, LLC – (SynCardia Total Artificial Heart, SynCardia Freedom Portable Driver)
- CardiacAssist, Inc. (TandemLife) – (TandemHeart System, LifeSPARC System)
- NuPulseCV – (iVAS (intravascular ventricular assist system) iVAS Portable System)
- Calon Cardio-Technology Ltd. – (MiniVAD LVAD, Calon VAD Platform)
- Miromatrix Medical Inc.-(Bioengineered LVAD, Biomimetic Cardiac Devices)
- CARMAT – (CARMAT Total Artificial Heart, CARMAT Hybrid Heart)
- Windmill Cardiovascular Systems – (HeartLander LVAD, Percutaneous VAD)
- Cirtec Medical – (VAD Engineering & Development Services, Cirtec's Neuromodulation and Cardiac Medical Devices)

## Segment Analysis

### By Product

Left Ventricular Assist Devices (LVAD): Dominating the Ventricular Assist Device Market

In 2023, the Left Ventricular Assist Devices (LVAD) segment dominated the ventricular assist device market, accounting for 83.5% of the market share, fueled by the rising frequency of LVAD implantations in heart failure patients. Abbott's HEARTMATE II LVAD has been used in more than 26,600 patients worldwide. As stated by the American College of Cardiology, hospital readmissions related to LVAD are frequently expensive and extended, indicative of the complex requirements of this patient demographic. In spite of difficulties, enhancements in patient functionality, quality of life, and survival rates, as emphasized by the American Heart Association, are driving the rapid adoption of LVADs. Cooperations between market participants seek to tackle organ deficits and increasing demand, particularly for those awaiting transplants.

### By Type of flow

Continuous Flow VADs: Leading the Market

In 2023, the continuous flow segment dominated the ventricular assist device (VAD) market, accounting for 89.9% of the market share. These devices are favored for their minimal noise, reduced maintenance needs, and fewer replacement parts compared to pulsatile VADs. Their reliability and ease of use make them a preferred option among medical professionals. Ongoing

advancements aim to further enhance their efficiency, solidifying their position as the top choice in VAD treatments.

### Pulsatile Flow VADs: A Fast-Growing Segment

The pulsatile flow segment is projected to grow fastest during the forecast period, driven by rising cases of heart failure and cardiovascular diseases. Mimicking the human heartbeat, pulsatile VADs provide better hemodynamics and natural blood perfusion, reducing complications seen in non-pulsatile systems. Increasing demand for advanced pulsatile systems offering both temporary and long-term cardiac support highlights a market shift toward physiologic mechanical circulatory support solutions.

### Ventricular Assist Device Market Segmentation

#### By Application

- Bridge to Transplant
- Destination Therapy
- Others (Bridge to Recovery, Bridge to Candidacy, and Others)

#### By Product

- Left Ventricular Assist Device
- Right Ventricular Assist Device
- Bi-Ventricular Assist Device
- Total Artificial Heart

#### By Type of Flow

- Pulsatile Flow
- Continuous Flow

#### By Design

- Implantable Ventricular Assist Device
- Transcutaneous Ventricular Assist Device

### Regional Analysis

In 2023, North America dominated the market with the largest share of the ventricular assist device (VAD) market, accounting for 58.1% of the market share. Reasons for this leadership can be explained by favorable reimbursement policies and increased awareness of VAD options, such as bridge-to-recovery, destination therapy and bridge-to-transplant, as well as by a high prevalence of obesity, which is an important risk factor for heart disease. In addition, the presence of an advance healthcare infrastructure in the U.S. will create immense opportunities for the market as it allows for higher treatment rates. Moreover, consumer-friendly insurance policies that minimize out-of-pocket expenses are contributing to the region's adoption.

The Asia-Pacific region is projected to experience the fastest growth in the Ventricular Assist Device (VAD) market, driven by technological innovations, the increasing prevalence of cardiovascular diseases, and the expansion of healthcare infrastructure. Nations such as China, Japan, India, and South Korea are seeing rising demand for VADs, fueled by an aging population and a high rate of heart failure cases. The region is also benefiting from significant investments in medical technology, with both government and private sectors focusing on enhancing healthcare capabilities and improving access to cutting-edge treatments.

#### Recent Developments

- In November 2022, Jarvik Heart, Inc. conducted a clinical trial for its ventricular assist device, Jarvik 2015, aimed at enhancing its product portfolio.
- In September 2022, Abbott expanded its capabilities by acquiring Walk Vascular, LLC, a company specializing in minimally invasive mechanical aspiration systems for blood clot removal.

Buy Full Research Report on Ventricular Assist Device Market 2024-2032 @

<https://www.snsinsider.com/checkout/4568>

#### Table of Contents – Major Key Points

1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Ventricular Assist Device Market by Application
8. Ventricular Assist Device Market by Product
9. Ventricular Assist Device Market by Type of Flow
10. Ventricular Assist Device Market by Design
11. Regional Analysis
12. Company Profiles
13. Use Cases and Best Practices
14. Conclusion

Speak with Our Expert Analyst Today to Gain Deeper Insights @

<https://www.snsinsider.com/request-analyst/4568>

#### About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the

world.

Akash Anand

SNS Insider Pvt. Ltd

415-230-0044

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/781688733>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.